ACIP SURVEY RESULTS
PREPARED BY KATHY BLANCO
PRESIDENT OF CHILDSCREEN
www.childscreen.org
Chairperson of VOSI STANDARD v50.3a, b, c...and so forth at www.voicesofsafety.com
Subcomitte Volunteers polling ACIP members include
LD Wedewer, Cindy Stolten, Julie Duffield, Audrey Adams, Tina Metz, Rita Hoffman, Donnet Richards, Deb Delp, Christa Tickle
ALL PARENTS OF AUTISTIC CHILDREN

The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Secretary, the Assistant Secretary for Health, and the Director, Centers for Disease Control and Prevention (CDC), regarding the most appropriate application of antigens and related agents (e.g., vaccines, antisera, immune globulins) for effective disease control in the civilian population. The ACIP develops written recommendations for the routine administration of vaccines to the pediatric and adult populations, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines. Additionally, the Committee reviews and reports regularly on existing immunization practices and recommends improvements in the national immunization efforts.

The Associate Director for Science serves as Executive Secretary of the committee, which consists of twelve members selected from authorities knowledgeable in the field of immunization practices and have multidisciplinary expertise in public health and the use of vaccines and immunologic agents in preventive medicine. The Committee has ex officio members from other government agencies and non-voting liaison representatives from medical and public health organizatons to assist in carrying out the functions of the Committee.

ACIP recommendations are published in the Morbidity and Mortality Weekly Report in the Recommendations and Reports series, and occasionally reprinted in other publications. ACIP recommendations are also used for the selection of vaccines and the schedule of immunizations by the Vaccine for Children (VFC) program.

http://www.cdc.gov/od/ads/acipnet3.htm

Standard to Delay Vaccinating Newborns

ALL MEMBERS WERE CONTACTED BY PHONE, FAX, EMAIL. Each parent was assigned to at least a minimum of 2 people of ACIP, some have done more, including myself over 15 members. We made sure that all were contacted in some form or another and sometimes we duplicated our efforts.
ALL ACIP OFFICIALS WERE UNCOOPERATIVE, NOT AVAILABLE, OR EITHER NOT RETURNING FAXES OR EMAILS OR PHONE, OR UPON INTERVIEW (IF WE WERE LUCKY) WERE NOT THE LEAST INTERESTED IN OUR SURVEY AND OUR RESEARCH. SOME WERE RUDE, SOME WERE UNCOMPLIMENTARY, UNWORKABLE and ALSO WERE TOLD AND WARNED "WE WERE CALLING THE LIST". WE ALSO HAD NO COOPERATION WITH THE STANDARDS QUESTIONS, INCLUDING "ARE YOU KIDDING ME" AS A RESPONSE. THE TYPICAL ANSWERS WERE ALSO "BUT VACCINATING THESE CHILDREN PROTECTS THEM", and or "WHO ARE YOU TO SAY THIS IS A STANDARD", and or "WE DON't LISTEN TO OUTSIDE PARTIES ON THESE ISSUES". I WOULD ASK THEM WHEN WE CAME TO SUCH DISCUSSIONS, SIR, ARE YOU SAYING THIS IS NOT A TRUE CONTRAINDICATION, BUT IT SAYS SUCH ON VACCINE VILES?" THEY SAID YES. THEN I ASKED WHY, and THEY WOULD REPLY "IT IS NOT YOURS TO QUESTION". THESE ARE INFACT ON MY PHONE LINE AS I TOLD THEM THEY WERE BEING RECORDED AS I INTERVIEWED THEM. I CAN PRESENT THOSE TO THE PRESIDENT OF ACIP FOR REVIEW AND TO AN ATTORNEY WE WILL SURELY HIRE.
I find it highly interesting that research proves that Hyper IgE is in fact a flagship OF intense source and study at present as to how it is related to immune system quality to viruses, toxins and allergenic anaphylaxis and atopy material. PLEASE SEE SUCH ABSTRACTS BELOW AND A LETTER BY DR BUTTRAM.
All negative votes must be resolved before any VOSI standard is approved.
VOSI will assume that all persons who do not vote approve the standard.
VOSI is cooperating with Childscreen, Inc. (www.childscreen.org) to develop
screening standards prior to vaccinating in order to significantly reduce
the Autism epidemic of 1 in 150 school age children. This standard is the
first step in accomplishing this goal.
THE FOLLOWING WERE CONTACTED
1. Meserlian 1 Modlin, John F. M.D. (603) 650-5459 Dartmouth Medical School Lebanon New Hampshire
2 Snider Jr., Dixie E. M.D. (404) 639-7240 Centers or Disease Control and Prevention Atlanta Georgia
3 Belshe, Robert B. M.D. (314) 577-8648 Pediatrics and Molecular Microbiology St. Louis Missouri
4 Hanson, I. Celine M.D. (512) 490-2505 Bureau of Communicable Disease Control Austin Texas
5 Birkhead, Guthrie S. M.D. (518) 402-5382 Center for Community Health Albany New York
6 Levin, Myron J. M.D. (303) 315-4620 Pediatric Infectious Diseases Denver Colorado
7 Brooks, Dennis A. M.D., M.P.H. (410) 243-1800 Johns Hopkins School of Medicine Baltimore Maryland
8 Offit, Paul A. M.D. (215) 590-2020 Section of Infectious Diseases Philadelphia Pennsylvania
9 Deseda, Jaime M.D. (787) 782-3141 San Jorge Children's Hospital San Juan Puerto Rico
10 Rennels, Margaret B. M.D. (410) 328-6919 Department of Pediatrics Baltimore Maryland
11 Salamone, John E. (202) 387-0600 National Italian American Foundation Washington D. C.
12 Word, Bonnie M. M.D. (732) 329-2433 Monmouth Junction New Jersey
13 Tompkins, Lucy S. M.D., Ph.D. (650) 725-3861 "Department of Medicine and Microbiology and Immunology" Stanford California
14 Zimmerman, Richard M.D. (412) 383-2377 Department of Family Medicine Pittsburgh Pennsylvania
15 Cheek, James E. M.D., M.P.H. (505) 248-4226 Division of Community and Environmental Health Albuquerque New Mexico
16 Slater, Eve M.D. (202) 690-7694 National Vaccine Program Office Washington DC
17 Diniega, Benedict M. M.D., Col. (703) 681-1711 "Preventive Medicine & Surveillance Office of the Assistant Secretary of Defense or Health Affairs" Falls Church Virginia
18 Graydon, T. Randolph (410) 786-9004 "Division of Advocacy and Special Issues Center for Medicaid & State Operations" Baltimore Maryland
19 Evans, Geoffrey S. M.D. (301) 443-4198 Division of Vaccine Injury Compensation H R S A Rockville Maryland
20 Heilman, Carole M.D. (301) 496-1884 Division of Microbiology and Infectious Disease Branch Bethesda Maryland
21 Midthun, Karen M.D. (301) 827-0655 "Office of Vaccine Research and Review Center for Biologics Evaluation and Research" Bethesda Maryland
22 Nichol, Kristin Lee M.D (612) 725-2085 University of Minnesota Minneapolis Minnesota
23 Mahoney, Martin M.D., Ph.D. (716) 845-3597 American Academy of Family Physicians Clarence New York
24 Turner, James C. M.D. (434) 9245471 American College Health Association Charlottesville VA
25 Clover, Richard D. M.D. (502) 852-3297 American Academy of Family Physicians Louisville Kentucky
26 Gall, Stanley M.D. (502) 852-5811 American College of Obstetricians and Gynecologists Louisville Kentucky
Meagher 27 Abramson, Jon M.D. (336) 716-2512 American Academy of Pediatrics Winston Salem North Carolina
28 Neuzil, Kathy M.D. (206) 764-2478 American College of Physicians Seattle Washington
Meagher 29 Baker, Carol M.D. (713) 7984790 American Academy of Pediatrics Houston Texas
30 Wilson, H. David M.D. (701) 777-2516 American Medical Association Grand Forks North Dakota
31 France, Eric K. M.D., M.S.P.H. (303) 360-1056 American Association of Health Plans Denver Colorado
32 Foster, Stephan L. Pharm.D. (901) 448-6806 American Pharmaceutical Association Memphis Tennessee
33 Salisbury, David M. M.D. London Department of Health
34 McKinney, W. Paul M.D. (502) 852-7945 Association of Teachers of Preventive Medicine Louisville Kentucky
35 Hershey, J. Henry M.D., M.P.H. (540) 3817100 "National Association of Country and City Health Officials (NACCHO)" Christianburg VA
contactor "tracking number" Name phone Affillitaion city state
36 Marchessault, Victor M.D. (613) 830-8860 "Biotechnology Industry Organization Canadian National Advisory Committee on Immunization" Cumberland Ontario
37 Neumann, David A. Ph.D. (301) 656-0003 National Coalition for Adult Immunization Bethesda Maryland
38 Siegel, Jane D. M.D. (214) 648-3561 "Healthcare Infection Control Practices Advisory Committee" Dallas Texas
39 Santos, Jose Ignacio "National Immunization Council and Child Health Program"
40 Katz, Samuel L. M.D. (919) 684-3734 Infectious Diseases Society of America Durham North Carolina
41 Jackson, Rudolph E. M.D. (404) 752-1703 National Medical Association Atlanta Georgia
42 Schaffner, William M.D. (615) 322-2037 Infectious Diseases Society of America Nashville Tennessee
43 Peter, Georges M.D. (401) 444-8360 National Vaccine Advisory Committee Providence Rhode Island
44 Germano, Geno (610) 902-4343 "Pharmaceutical Research and Manufacturers of America" St. Davids Pennysylvania
45 Kovachs, Gloria (404) 639-1869 CDC
THIS ONCE AGAIN PROVES THAT OFFICIALS WHO SHOULD LISTEN AND OBEY FEDERAL LAW ARE NOT DOING SO. WE SHALL SEEK LEGAL ADVICE and PROTECTION UNDER THE LAW TO ACCOMPLISH THE GOAL AND STANDARD OF DELAYING VACCINATION IN A COMPRIMISED CHILD.
Abstract The Lancet
Volume 351, Number 9114 16 May 1998

Research letters

Raised serum IgE associated with reduced responsiveness to DPT vaccination during infancy
Susan L Prescott, Peter D Sly, Patrick G Holt
Th-2-skewed immunity against allergens in association with raised IgE antibody production is a hallmark of the atopic phenotype, and contrasts with the Th-1-like pattern of immunity expressed in non-atopics. Recent studies indicate that these differing responses are commonly programmed into immunological memory during early childhood, and represent the outcome of competition between mutually antagonistic IL-4-secreting Th-2 cells and IFN-secreting Th-1 cells which are activated by repeated allergen exposure. TVW Telethon Institute for Child Health Research, PO Box 855, West Perth 6872, Western Australia (PG Holt); and Department of Paediatrics, University of Western Australia, Perth
Neonatal Umbilical Cord IgE Tests: Rationale for Their
Use in Screening Infants for Impaired Immunity and
Increased Vulnerability to Childhood Vaccines
Serum IgE: Its Physiology and Biological Effects
There are four major categories of immunoglobulins in the human system: 1) the IgG fraction, or gamma globulins, which carry long-term immunity, 2) the IgM fraction, or macroglobulins, which provide immediate but nonspecific protection with acute infections, 3) the Secretory IgA of the mucous membranes, sometimes referred to as "antiseptic paint," and 4) the IgE system. All immunoglobulins are produced by lymphocytes located in the bone marrow, a class known as B-lymphocytes.
Some texts speculate that the IgE antibody system originally evolved as a protection against intestinal parasites. Elevated levels of IgE antibodies are found in patients with parasitic infestation and atopic/hypersensitivity diseases such as asthma, eczema, and hay fever, but they do not seem to be related to autoimmune conditions. In some children with atopic diseases plasma IgE antibodies may be elevated 5 to 20 times normal. The IgE molecule has a high-affinity for the surface membranes of mast cells and basophils, and once exposed to or cross-linked with allergenic antigens, such as pollen or mold, pro-inflammatory lipid-derived mediators are released which may produce immediate hypersensitivity reactions with vascular leakage, tissue swelling, inflammation, and/or broncho-constriction.
During fetal life lymphocytes produce very little immunoglobulins under ordinary circumstances, presumably due to the protected environment in the uterus (although the fetus can produce IgM and IgA when there have been prenatal infections). For this reason the IgG levels in the term infant are similar to maternal levels as a result of transplacental transfer. However, no other class of immunoglobulin passes the placental barrier, including IgE, so that these are usually absent in the newborn infant.
It is important to add that with breast feeding there is some transfer of antibodies from the mother, especially IgA, lysozyme, and lactoferrin, along with large numbers of lymphocytes and monocytes during the first two months following birth to provide protection while the baby's own immune system is slowly maturing, a process requiring a number of years. (1)
Rationale for Use of Neonatal Umbilical Cord IgE as a Screening Test
Very few today would question that we are dealing with an increasing pattern of sickness in today's children as compared with earlier generations. Neurobehavioral problems are epidemic including autism, learning disabilities, and attention deficit hyperactivity disorder. If you doubt this, ask any experienced elementary school teacher who has been teaching for a number of years. In my experience, and I have talked with many of them, their answers have been unanimous and emphatic that they are now seeing a much greater incidence of these disorders with visible increases almost by the year. The same can be said for allergic disorders and general patterns of sickness.
Up until recently some have contended that the increase in these disorders has been due to better diagnosis, but this is no longer the case as reflected by current CDC (Center for Disease Control) statistics. What then are the causes of this ominous health trend in our children? There are clues which relate in part to vaccines. Epidemiologic studies from England, (2) Sweden, (3) Africa, (4) and 5) New Zealand have consistently shown a much greater incidence of atopic disorders in fully vaccinated children as compared to those with limited or no vaccines.
F Imani and KE Kehoe, in following up on a study showing that the measles virus infections (synergizing with Interleukin-4) cause an IgE class switching of B-Lymphocytes, found the same switching from the MMR vaccine leading to an increase in the expression of IgE (and by inference away from the protective IgG and IgM antibodies. (6)
There is a relatively rare condition known as the "hyperimmunoglobulin E syndrome" (HIE) which could serve as a model. HIE syndrome is characterized by high IgE serum levels, chronic dermatitis, and recurrent bacterial infections with Staphylococcus aureus and other Polysaccharide encapsulated organisms. The proposed mechanism arises from insufficient suppressor T cells, which is manifested in part by reduced production of interferon (IFN)-alpha and tumor necrosis factor. (7) For our purpose here it is important to point out that the same abnormal antibody responses have been documented in some patients in response to vaccines. (8) In addition, studies of children with HIE by Leung et al at the Children's Hospital of Boston found significantly impaired antibody response to recurrent Staphylococcal infections and to Haemophilus influenzae vaccine.(9) (As an explanation for this impaired antibody response demonstrated in the Leung study, it is reasonable to assume that a shunting of the genetic antibody production towards increased pro-inflammatory IgE would be accompanied by a shunting away from the protective IgG and IgM antibodies, although this has yet to be demonstrated in the laboratory).
In brief summary of the above, we have the model of the Hyperimmunoglobulin E Syndrome in which impaired immune response to both bacterial infections and vaccines have been documented. We know that, although maternal IgG is the only class of antibodies that passes to the fetus through the placental membranes, fetuses have been known to generate their own IgM and IgA with prenatal infections. Although apparently IgE has not been found in newborns to date, according to references that I have seen, are there situations arising today in which a fetus may be stimulated to produce its own IgE? I believe that there are.
Most children today are third generation vaccine recipients. Mention has been made above of marked increases in allergic disorders in fully vaccinated children as compared to those with limited or no vaccines, a process that may well be compounded from one generation to the next. At some point this increased proneness to IgE-related hypersensitivity may be communicated to the fetus. Should we not be finding out?
Gross Deficiencies in Safety Testing of Childhood Vaccines and Their Consequences
There are at present growing public and professional concerns about the safety of currently mandated childhood vaccines, as reflected by a series of annual Congressional hearings in Washington DC that have taken place since 1999, sponsored by U.S. House Government Reform Committee under the chairmanship of Congressman Dan Burton. Out of these hearings there has emerged a consistent pattern of deficiencies in basic science of safety testing. As a result of these deficiencies large numbers of adverse vaccine reactions may be taking place unrecognized as to their true nature, especially delayed-type reactions.
Based on these hearings, as a general statement scientific evidence does not support the safety of immunizations in that pre-licensing safety surveillance periods on vaccines have been limited to short periods only: days to several weeks. There have been no long-term (months or years) safety studies on any childhood vaccine in use today. In addition, there have been no systematic before-and-after studies on the effects of vaccines on the neurologic, immunologic, or other systems of the body, studies which ordinarily are considered indispensable in forming a foundation of basic science in the field of medicine.
Although numerous examples could be provided, perhaps the most flagrant example is that of thimerosal, the mercurial additive, which has been used in vaccines since the 1930s. As we now know, prior to June, 1999 when pharmaceuticals began removing thimerosal from vaccines, some babies received as much as 50 or 75 times the allowed safe dose of mercury in a given day, depending on the combinations of vaccines, according to current US Environmental Protection Agency (EPA) standards. It was only after this issue was raised in the Congressional hearings, with subsequent outrages expressed by some, that the pharmaceuticals began in earnest to remove thimerosal from the vaccines.
In addressing this issue on June 20, 2002, Congressman Burton made the following comment:

"(Do) you mean to tell me that since 1929 we have been using thimerosal and the only test that you know of was done in 1929, and every one of those people had meningitis, and they all died?"

Congressman Burton went on to state that there could be criminal penalties for any government agency that knew about the dangers of thimerosal and did nothing to protect the children.
Conclusions
To the best of my knowledge, most meaningful safety research for childhood vaccines has been privately funded, government agencies having largely failed to provide for this need. The same is true for the present proposed study of neonatal cord blood IgE tests. Aside from its inherent scientific attraction of exploring a relatively new and unknown area, as far as I am aware it will have the distinction of being the first test specifically designed to screen for infants with increased vulnerability to adverse vaccine reactions. It is a precedent that is long overdue.
Harold E Buttram, MD
January 4, 2003
References

(1) Information on physiology of IgE antibodies were found in Williams Text of Hematology, Sixth Edition, Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U (Editors), McGraw-Hill Publ., New York, 2001; Nelson Textbook of Pediatrics, Sixteenth Edition, Behrman RE, Kliegman, RM, Jenson HB (Editors), WB Saunders Co, Philadelphia, 2000; Immuno-Biology; the Immune System in Health and Disease, Fourth Edition, Janeway CA, Travers P, Walport M, Capra JD (Editors), Garland Publ, New York, 1999.

(2) Odent MR, Pertussis vaccine and asthma; is there a link? JAMA, 1994; 271:229-231.

(3) Alm JS et al, Atopy in children of families with anthroposophic lifestyle, Lancet,

May 1, 1999; 353:1485-1488.

(4) Shaneen SO et al, Measles and atopy in Guinea-Bissau, Lancet, June 19, 1996; 347:1792-1796.

(5) Kemp T et al, Is infant immunization a risk factor for childhood asthma or allergy?, Epidemiology, November, 1997; 8(6):678-680.

(6) Imani F, Kehoe KE, Infection of human B lymphocytes with MMR vaccine induces IgE class switching, Clinical Immunology, Sept., 2001; 100(3):355-361.

(7) See reference (1), pages 842-843.

(8) Sheerin KA, Buckley RH, Antibody responses to protein, polysaccharide, and pili X174 antigens in the hyperimmunoglobulin E (hyper IgE) syndrome, J Allergy Clin Immunol, 1991; 87:803.

(9) Leung DY, Ambrosino DM, Arbeit RD et al, Impaired antibody responses in the hyperimmunoglobulin E syndrome, J Allergy Clin Immunol, June, 1988; 81(6): 1082-7.